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Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma,
and adenomatous nodules via a tissue microarray method
1,

2

1

3

4

5

Peyker TEMİZ *, Gizem AKKAŞ , Nalan NEŞE , Fazilet UĞUR DUMAN , Cansu KARAKAŞ , Yamaç ERHAN
1
Department of Pathology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
2
Department of Pathology, Faculty of Medicine, Dumlupınar University, Evliya Çelebi Training and Research Hospital, Kütahya, Turkey
3
Laboratory of Pathology, Karşıyaka State Hospital, İzmir, Turkey
4
Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
5
Department of Surgery, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
Received: 11.06.2014

Accepted/Published Online: 17.10.2014

Printed: 30.07.2015

Background/aim: To identify the role of gene products associated with apoptosis and cell cycle in the pathogenesis of thyroid follicular
neoplasm.
Materials and methods: Thirty follicular adenomas (FAs), 16 follicular carcinomas (FCs), and 20 adenomatous nodules (ANs) were
investigated with immunohistochemical staining of p16, p21, p27, p53, Bcl-2, Bax, Bcl-xL, and cyclin D1 via a tissue microarray method.
Results: Bcl-2 showed a significant difference between the benign groups (AN and FA) and the malignant group (FC). Bax was
significantly higher in the FC group. p53 was lowest in the AN group and highest in the FC group with significant differences between
the groups. p16 was significantly higher in the FC group than in the other groups. There was a significant difference between the AN
group and neoplastic lesions in terms of p21 staining. The number of cases with positive p27 was lower in the AN group than the
neoplastic groups. There was no significant difference in terms of Bcl-xL and cyclin D1.
Conclusion: Cell cycle modulators, led by the Bcl-2 family, played an important role in the pathogenesis of thyroid follicular neoplasm,
and p53, p16, and p21 in particular played a role in the carcinogenesis of FC.
Key words: Thyroid, follicular neoplasm, p16, p21, p27, p53, Bcl-2, Bax, Bcl-XL, Cyclin D1, immunohistochemistry, tissue microarray

1. Introduction
Despite various studies on cell cycle modulators such as
p16, p21, p27, p53, Bcl-2, Bax, Bcl-XL, and cyclin D1 in
thyroid lesions, the current literature includes no largescale study that evaluates all of these as a whole. The present
study aimed to identify the role of these gene products,
which are associated with apoptosis and cell cycle and are
intercorrelated, in pathogenesis within a broad spectrum
of samples of follicular carcinomas (FCs), follicular
adenomas (FAs), and adenomatous nodules (ANs).
2. Materials and methods
2.1. Cases
In the present study, 30 FA and 16 FC cases, which were
diagnosed based on the thyroidectomy materials or the
blocks sent for consultation between 2006 and 2010 in
the pathology department of our university hospital,
* Correspondence: peykerdemireli@gmail.com

were evaluated. Twenty cases of AN were included as the
control group.
The diagnoses were verified by reexamining the
preparations stained with hematoxylin & eosin (HE).
The preparations and paraffin blocks that contained the
higher amounts of tissue and represented the lesions were
selected.
2.2. Preparation of tissue microarray blocks and sections
In order to obtain suitable blocks for the tissue microarray
(TMA) method, routine paraffin and wax (Merck Product
No. 1115449020, Darmstadt, Germany) were mixed at a
proportion of 1/10 (wax/paraffin) and melted at 64 °C.
Blocks were obtained using a 3DHISTECH Ltd. Manuel
TMA Kit (Budapest, Hungary). Using a TMA punch
pencil, 2 mm of target tissues were taken from the paraffin
blocks with marked lesion area and 16–18 tissue samples
were embedded in each TMA block. One slide was
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prepared from each block for HE staining and 10 slides
were prepared for immunohistochemical staining.
2.3. Immunohistochemical staining method
Immunohistochemical staining was performed in 4-µm
sections taken from TMA blocks onto the positive-load
specific slides via a fully automatic device (Ventana Benchmark
XT, Tucson, AZ, USA) and relevant immunohistochemical
kit (DAB Substrate System, AEC Detection Kit, EZ Prep,
LCS, SSC Solutions, RBS, Amplification, Protease, Block
Solutions, Hematoxylin; Ventana).
For immunohistochemical staining, purified mouse
antihuman p16 (INK4) Ab-4 (16P04, MS-887-P1,
LabVision/NeoMarkers, Fremont, CA, USA; 1/25
dilution-40 min), mouse antihuman p21Waf1 monoclonal
antibody (Clone SPM306, E6330, Spring Bioscience,
Pleasanton, CA, USA; 1/50 dilution-1 h), rabbit
antihuman p27Kip1 polyclonal antibody (E2600, Spring
Bioscience; 1/100 dilution-12 min), rabbit antihuman
p53 monoclonal antibody (Clone SP5, M3050, Spring
Bioscience; 1/100 dilution-48 min), rabbit anti-Bcl 2 alpha
polyclonal antibody (E17980, Spring Bioscience; 1/200
dilution-44 min), rabbit anti-Bax monoclonal antibody
(Clone SP47, M3470, Spring Bioscience; 1/50 dilution-32
min), rabbit antihuman bcl-xL polyclonal antibody
(E3370, Spring Bioscience; 1/200 dilution-16 min), and
rabbit antihuman cyclin D1 monoclonal antibody (Clone
SP4, M3040, Spring Bioscience; 1/100 dilution-32 min)
were used. Amplification was performed only with p21
and Bcl-2. Positive and negative controls were used in each
immunohistochemical staining.
The preparations with immunohistochemical staining
were screened by 3DHISTECH Kft. in Budapest, Hungary
and digital images that would enable computed analysis
were created.
2.4. Evaluation of immunohistochemical outcomes
All evaluations were performed via computer using
the Pannoramic Viewer 1.14 and DensitoQuant 1.14
applications of the 3DHISTECH TMA Module 1.14
program (Budapest, Hungary). Initially, orientation of
images was provided using the 3DHISTECH Panoramic
Viewer 1.14 application. Thereafter, Bcl-2, Bcl-xL, and
Bax cytoplasmic staining, as well as p53 nuclear and
cytoplasmic staining, were analyzed using a DensitoQuant
1.14 application. Three lesion areas with similar size and
with the densest staining were marked on each image. The
highest staining percentage in these 3 areas was considered
in this study.
Evaluation of p16, p21, p27, and cyclin D1, which cause
nuclear staining, was performed on digital images with
100× and 400× magnifications by 2 separate pathologists.
Three consequent areas including 200 cells were counted
and the highest staining percentage was taken as the basis
for study.
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2.5. Statistical analysis
Data were analyzed using the SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA). Correlation was analyzed using Pearson
and Spearman correlation analyses. The Kruskal–Wallis
test was used for comparison of more than 2 independent
groups. The Mann–Whitney U test was used to compare
differences between 2 independent groups when the
dependent variable was either ordinal or continuous. The
Wilcoxon test was used when comparing 2 related samples,
matched samples that came from the same population. P <
0.05 was considered statistically significant.
3. Results
3.1. Age and sex
The age of patients ranged between 17 and 70 years (mean:
44.13 ± 12.89 years) in the FA group (the majority (36.7%)
in the fifth decade), 23 and 70 years (mean: 47.43 ± 14.97
years) in the FC group (majority in the third (18.8%) and
sixth (18.8%) decades), and 21 and 59 years (mean: 44.00 ±
11.25 years) in the AN group (majority (40%) in the sixth
decade). Twelve (75%) of the FC, 22 (73.3%) of the FA,
and 15 (75%) of the AN patients were females and 4 (25%)
of the FC, 8 (26.7%) of the FA, and 5 (25%) of the AN
patients were male.
With regard to the age distribution of all groups, it was
determined that the majority of the patients were adults
and females. No significant difference was found between
the groups in terms of age (P > 0.05).
3.2. Results of immunohistochemical staining
It was detected that Bcl-2, Bax, and Bcl-xL caused
cytoplasmic staining, p53 caused cytoplasmic and
nuclear staining, and p16, p21, p27 and cyclin D1 caused
nuclear staining in the neoplastic and nonneoplastic
thyrocytes (Figure). The mean staining percentage
of 8 immunohistochemical markers among groups is
demonstrated in the Table.
The percentage of Bcl-2 and Bcl-xL staining was high in
all groups. The highest Bax staining percentage was in the
FC group, although more than half of overall lesions were
negative with Bax. p53 was the lowest in the AN group and
the highest in the FC group. p16 was significantly higher
in the FC group than the other groups. p21 staining was
lower in the AN group than in the FA and FC groups.
The number of cases with positive p27 was lower in the
AN group than the neoplastic groups but p27 staining
percentages of the groups were close to each other. The
highest cyclin D1 staining percentage was in the FA group,
whereas the lowest percentage was in the AN group.
The percentages of p53, p16, and p21 staining showed
significant differences between the AN group and the
other 2 groups containing neoplastic lesions (P < 0.05
for each). There were significant differences among the 3
study groups with these stainings (P < 0.05 for each).
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Figure. Cytoplasmic staining of Bcl-2, Bax, and Bcl-xL; nuclear and cytoplasmic staining of p53; nuclear
staining of p16, p21, p27, and Cyclin D1.
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Table. The mean staining percentage of immunohistochemical markers among groups.
Immunohistochemical marker

Follicular adenoma

Follicular carcinoma

Adenomatous nodule

Bcl-2

71.69 ± 24.58

88.56 ± 9.84

85.72 ± 12.50

Bax

9.51 ± 17.72

33.38 ± 36.47

3.88 ± 7.26

Bcl-xL

89.95 ± 17.90

96.02 ± 6.92

94.24 ± 7.88

p53

7.14 ± 16.14

28.89 ± 35.41

1.38 ± 2.00

p16

10.96 ± 20.71

32.33 ± 38.49

1.05 ± 1.35

p21

25.39 ± 20.53

34.68 ± 22.02

12.89 ± 13.87

p27

3.62 ± 4.49

3.26 ± 5.29

3.60 ± 9.30

Cyclin D1

32.26 ± 26.57

20.00 ± 14.71

19.15 ± 18.09

There were significant differences between benign (FA
and AN) and malignant (FC) groups in percentages of bcl2, Bax, and p16 staining (P < 0.05 for each).
No significant difference was observed among the
groups in terms of bcl-xL, p27, and cyclin D1 staining (P
> 0.05).
In the FC group, there was a highly positive correlation
between the percentages of Bcl-2 and Bcl-xL staining
(r = 0.50). In the FC and FA groups, a highly positive
correlation was found between the percentages of Bax and
p53 staining (r = 0.79 and r = 0.85, respectively).
4. Discussion
Age and sex distribution of the study groups was in line
with the classical information on thyroid lesions (1,2); the
majority of the patients were adult females. No significant
difference was determined among the groups in terms of
age (P > 0.05).
In line with the literature, both benign and malignant
samples in all study groups showed cytoplasmic Bcl-2
staining (3–7) with the highest staining percentage in the
FC group. Bcl-2 stainings being significantly different in
the FA and AN groups (represented as benign lesions)
as compared to the FC groups (represented as malignant
lesions) can be interpreted as demonstrating the way
that the apoptosis pathway, in which Bcl-2 plays a role, is
different between benign and malignant lesions. The fact
that the FC group showed a higher Bcl-2 expression than
the other groups indicates prolonged lifetime in tumor
cells and the role of Bcl-2 in carcinogenesis.
Approximately one-third of the FC group and more
than half of the lesions in the other groups showed no
Bax staining. The low percentage of immunochemical Bax
staining in the AN group is consistent with the literature
(5,8,9).
In the FC and FA groups, a highly positive correlation
was found between Bax and p53 (r = 0.79 and r = 0.85,

868

respectively). Similar correlations have been described in
the literature and it has been reported that Bax also shows
a high staining percentage in thyroid cancers, in which
the percentage of p53 staining is high (4,6,8). Correlation
between Bax and p53 suggests that the Bax gene and p53,
which is the transcriptional activator of Bax, together have
an effective role in the pathogenesis of neoplastic lesions.
It has been suggested that Bcl-xL shows no or weak
staining in regular follicular cells and is more highly
expressed in thyroid carcinomas originating from follicular
cells (7,10). In the present study, the facts that there was
no significant difference among the groups (despite the
highest staining percentage being in the FC group) and
that all of the FA, FC, and AN groups showed positive BclxL staining and all had a high staining percentage were
inconsistent with the literature.
A highly positive correlation (r = 0.50) between the
percentages of Bcl-2 and Bcl-xL staining suggested a
shared antiapoptotic effect.
With regard to the overall members of the Bcl-2
gene family, it was concluded that Bcl-2, Bax, and BclxL showed extensive positivity in FC, findings that were
largely consistent with the literature, and all members of
this gene family, Bcl-2 being most prominent, had a role in
the pathogenesis of tumors derived from thyroid follicular
epithelial cells.
It has been suggested in the literature that normal
thyroid tissue and benign thyroid lesions show no p53
staining and that p53 mutation is seen in 15% of overall
thyroid carcinomas, being higher in undifferentiated and
poorly differentiated thyroid carcinomas. Reported p53
positivity varies between 30% and 90% in FCs and between
15% and 33.3% in FAs (8,11–17).
The results of the present study concerning p53
are consistent with the literature (3,5,8,11,13–23) with
remarkably high p53 staining in the carcinoma group.
The number of stained lesions and the staining percentage
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were significantly lower in the AN group compared to
the neoplastic groups. Consideration of these findings,
together with those reported in the literature, suggests that
p53 is a predictor for malignancy and has a role in tumor
pathogenesis.
While previous research found no p16 staining in
nonneoplastic lesions or normal thyroid tissue, p16
positivity was observed in thyroid papillary carcinoma
and FCs. It has been suggested that p16 plays an important
role in transforming the benign form into the malignant
form in follicular thyroid cells (24–26). Significantly low
p16 staining in the AN group compared to the FA group
and particularly the FC group and, in contrast, the high
p16 staining in the FC group are in line with information
in the literature and suggest that p16 has a role in the
tumorigenesis of neoplasms derived from follicular
epithelial cells, particularly in malignant transformation.
p21 staining, observed in all the FA and FC lesions, is
rarely observed in normal thyroid cells and hyperplasia but
is observed at 10%–28% in FAs. Although there are studies
reporting that p21 has no importance in patient survival,
there are also studies suggesting that it has importance
in tumor aggression and is high in patients with fatal
progression (27–30). Staining characteristics with p21 in
the present study are consistent with those reported in
the literature and the difference between neoplastic and
nonneoplastic lesions in particular attracts attention to the
role of p21 in the pathogenesis of follicular neoplasm.
Nuclear p27 positivity has been reported to be higher
in normal thyroid tissue and multinodular goiter than in
tumoral tissues. Stronger positivity has been detected
in cases of papillary hyperplasia than in cases of thyroid
papillary carcinoma and it has been suggested that it could
be helpful in differentiating benign from malignant papillary
proliferations. Higher p27 positivity has been observed in

FA cases as compared to the FC and TPC-follicular variants
(31–34). It has been reported that loss of p27 expression
indicates tumor aggression, poor differentiation, and
metastasis capacity in thyroid carcinomas (32–35). In the
present study, the results concerning p27 did not completely
reflect the loss of p27 expected in thyroid carcinomas.
Higher p27 staining was also reported in oncocytic
lesions as compared to nononcocytic tumors (36–38). In
the present study, the reason for higher p27 staining than
expected instead of loss of p27 might be the higher staining
percentage in the oncocytic lesions in both the FA and FC
groups. Moreover, the absence of poorly differentiated cases
in the FC group might have been effective in obscuring the
loss of p27 expression.
Cyclin D1, which has a nuclear staining character, is
not observed in normal thyroid cells. Results concerning
staining in hyperplastic lesions are contradictory.
Positivity has been demonstrated in FA, FC, thyroid
papillary carcinoma, and Hurtle cell carcinoma (39–46).
In the present study, there was no case without cyclin D1
staining in the FA, FC, and AN groups and no significant
difference was found among the groups in terms of cyclin
D1 staining. Although cyclin D1 staining in the present
study was observed in all cases, expression in malignant
lesions is not as high as suggested.
In conclusion, the present study revealed that cell cycle
modulators, led by the Bcl-2 family, played an important
role in the pathogenesis of follicular cell neoplasms,
particularly with significant roles of p53, p16, and p21 in
the pathogenesis of FCs.
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